**ATTY DOCKET No. 4121-135** 

## SECTION I

## Complete Listing of the Claims

No amendments are made to the claims. The following is a complete listing of the claims of the application.

- (Previously presented) A F<sub>V</sub> antibody construct having variable domains for CDl6 and a CD30 but no constant domains and inducing a regression of Hodgkin's disease in vivo.
- 2. (Previously presented) The  $F_V$  antibody construct according to claim 1, wherein the CD16 is derived from natural killer cells (NK cells).
- (Previously presented) The F<sub>V</sub> antibody construct according to claim 1, wherein the CD30 is derived from a member selected from the group consisting of: Hodgkin's disease or Reed-Sternberg cells.
- 4. (Previously presented) The  $F_V$  antibody construct according to claim 1, wherein one binding site is present each.
- (Previously presented) The F<sub>v</sub> antibody construct according to claim 4, encoded by the expression vector pKID16-30 (DSM 12960).
- 6. (Previously presented) The F<sub>V</sub> antibody construct according to claim 1, wherein two binding sites are present for each.
- 7. (Withdrawn) An expression vector, coding for the F<sub>V</sub> antibody construct according to claim 1.
- 8. (Withdrawn) The expression vector according to claim 7, which is pKID16-30 (DSM 12960).
- 9. (Withdrawn) A transformant, containing the expression vector according to claim 7.

- 10. (Withdrawn) A method of producing the F<sub>v</sub> antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.
- 11. (Withdrawn) A kit comprising:
  - (a) an  $F_{\rm V}$  antibody construct having binding sites for an CDI6 receptor and a CD30 surface protein

and/or

- (b) an expression vector coding for said F<sub>V</sub> antibody construct, and
- (c) at least one auxiliary substance selected from the group consisting of buffers, solvents, carriers, controls and markers, wherein one or more representatives of the individual components may be present.
- 12. (Withdrawn) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F<sub>V</sub> antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.
- 13. (Withdrawn) A method according to claim 12, wherein the cells are tumor cells.
- 14. (Withdrawn) A method according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
- 15. (Previously presented) The F<sub>V</sub> antibody construct according to claim 2, wherein the CD30 is derived from a member selected from the group consisting of: Hodgkin's disease or Reed-Sternberg cells.
- 16. (Withdrawn) An expression vector, coding for the F<sub>V</sub> antibody construct according to claim 15.
- 17. (Withdrawn) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F<sub>V</sub> antibody construct having binding sites for an CD16 receptor and a CD30 surface protein, wherein the CD16 receptor is derived from natural killer

ATTY DOCKET NO. 4121-135

cells (NK cells), and wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

- 18. (Withdrawn) A transformant, containing the expression vector according to claim 8.
- 19. (Previously presented) The  $F_v$  construct of claim 1, wherein said  $F_v$  antibody construct comprises elements (a) and (b) joined via a peptide linker:
- (a) a VH domain of an anti-CD16 antibody and a VL domain of an anti-CD30 antibody, the domains being joined by a peptide linker; and
- (b) a VH domain of an anti-CD30 antibody and a VL domain of an anti-CD16 antibody, the domains joined by a peptide linker.
- 20. (Withdrawn) A method of treatment of a tumor comprising the step of administering the F<sub>v</sub> antibody construct according to claim 1.
- 21. (Withdrawn) The method of claim 20, wherein the treatment comprises the lysis of Hodgkin's disease or Reed-Sternberg cells.
- 22. (Previously presented) The F<sub>V</sub> antibody construct according to claim 1, wherein said F<sub>V</sub> antibody is capable of inducing a more intense tysis of CD30 carrying cells *in vitro* than bimAbHRS-3/A9 (DSM ACC2142).

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK